生物活性 | |||
---|---|---|---|
描述 | Ozenoxacin is a nonfluorinated quinolone antibacterial, which shows potent activities against the main microorganisms isolated from skin and soft tissue infections. Ozenoxacin (OZN) shows potent antibacterial activities against clinical isolates of Gram-positive microorganisms, with MICs ranging from 0.008 to 4 mg/L. Ozenoxacin shows good activities against strains of MRSA, MSSA, MSSE, and MRSE with 2, 3, or 4 mutations in the gyrA and grlA (parC) genes[1]. Ozenoxacin inhibits MSSA strains and S. agalactiae strains, with the rates of resistance of >10-10 and 5.3 × 10-10, respectively. The maximum MIC value for mutant strains is 8 mg/L for ozenoxacin[2]. Ozenoxacin, a novel non-fluorinated topical quinolone antimicrobial, has demonstrated efficacy in impetigo. In vitro studies have demonstrated high potency of ozenoxacin against staphylococci and streptococci including resistant strains of S. aureus. Clinical trials of ozenoxacin in patients with impetigo reported high clinical and microbiological success rates[3]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.75mL 0.55mL 0.28mL |
13.76mL 2.75mL 1.38mL |
27.52mL 5.50mL 2.75mL |
参考文献 |
---|